337 related articles for article (PubMed ID: 24313774)
21. Baseline asthma burden, comorbidities, and biomarkers in omalizumab-treated patients in PROSPERO.
Chipps BE; Zeiger RS; Luskin AT; Busse WW; Trzaskoma BL; Antonova EN; Pazwash H; Limb SL; Solari PG; Griffin NM; Casale TB
Ann Allergy Asthma Immunol; 2017 Dec; 119(6):524-532.e2. PubMed ID: 29054589
[TBL] [Abstract][Full Text] [Related]
22. A recombinant humanized anti-IgE monoclonal antibody (omalizumab) in the therapy of moderate-to-severe allergic asthma.
D'Amato G; Piccolo A; Salzillo A; Noschese P; D'Amato M; Liccardi G
Recent Pat Inflamm Allergy Drug Discov; 2007 Nov; 1(3):225-31. PubMed ID: 19075985
[TBL] [Abstract][Full Text] [Related]
23. Looking for Airways Periostin in Severe Asthma: Could It Be Useful for Clustering Type 2 Endotype?
Carpagnano GE; Scioscia G; Lacedonia D; Soccio P; Lepore G; Saetta M; Foschino Barbaro MP; Barnes PJ
Chest; 2018 Nov; 154(5):1083-1090. PubMed ID: 30336944
[TBL] [Abstract][Full Text] [Related]
24. Application of structured statistical analyses to identify a biomarker predictive of enhanced tralokinumab efficacy in phase III clinical trials for severe, uncontrolled asthma.
Gottlow M; Svensson DJ; Lipkovich I; Huhn M; Bowen K; Wessman P; Colice G
BMC Pulm Med; 2019 Jul; 19(1):129. PubMed ID: 31315668
[TBL] [Abstract][Full Text] [Related]
25. Monoclonal antibodies for the treatment of refractory asthma.
Hambly N; Nair P
Curr Opin Pulm Med; 2014 Jan; 20(1):87-94. PubMed ID: 24275927
[TBL] [Abstract][Full Text] [Related]
26. Safety and application of induced sputum analysis in childhood asthma.
Covar RA; Spahn JD; Martin RJ; Silkoff PE; Sundstrom DA; Murphy J; Szefler SJ
J Allergy Clin Immunol; 2004 Sep; 114(3):575-82. PubMed ID: 15356559
[TBL] [Abstract][Full Text] [Related]
27. Effects of adding omalizumab, an anti-immunoglobulin E antibody, on airway wall thickening in asthma.
Hoshino M; Ohtawa J
Respiration; 2012; 83(6):520-8. PubMed ID: 22236804
[TBL] [Abstract][Full Text] [Related]
28. Effectiveness of omalizumab in non-allergic severe asthma.
Domingo C; Pomares X; Angril N; Rudi N; Amengual MJ; Mirapeix RM
J Biol Regul Homeost Agents; 2013; 27(1):45-53. PubMed ID: 23489686
[TBL] [Abstract][Full Text] [Related]
29. Retrospective Study on the Association of Biomarkers With Real-world Outcomes of Omalizumab-treated Patients With Allergic Asthma.
Kavati A; Zhdanava M; Ortiz B; Lecocq J; Schiffman B; Pilon D; Ho H; Lefebvre P; Stone B
Clin Ther; 2019 Oct; 41(10):1956-1971. PubMed ID: 31563391
[TBL] [Abstract][Full Text] [Related]
30. Can biomarkers help us hit targets in difficult-to-treat asthma?
Fricker M; Heaney LG; Upham JW
Respirology; 2017 Apr; 22(3):430-442. PubMed ID: 28248008
[TBL] [Abstract][Full Text] [Related]
31. Biomarkers for severe eosinophilic asthma.
Yancey SW; Keene ON; Albers FC; Ortega H; Bates S; Bleecker ER; Pavord I
J Allergy Clin Immunol; 2017 Dec; 140(6):1509-1518. PubMed ID: 29221581
[TBL] [Abstract][Full Text] [Related]
32. A systematic review and meta-analysis: tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils).
Petsky HL; Cates CJ; Lasserson TJ; Li AM; Turner C; Kynaston JA; Chang AB
Thorax; 2012 Mar; 67(3):199-208. PubMed ID: 20937641
[TBL] [Abstract][Full Text] [Related]
33. Refractory asthma - beyond step 5, the role of new and emerging adjuvant therapies.
Kane B; Fowler SJ; Niven R
Chron Respir Dis; 2015 Feb; 12(1):69-77. PubMed ID: 25492977
[TBL] [Abstract][Full Text] [Related]
34. Omalizumab modulates bronchial reticular basement membrane thickness and eosinophil infiltration in severe persistent allergic asthma patients.
Riccio AM; Dal Negro RW; Micheletto C; De Ferrari L; Folli C; Chiappori A; Canonica GW
Int J Immunopathol Pharmacol; 2012; 25(2):475-84. PubMed ID: 22697079
[TBL] [Abstract][Full Text] [Related]
35. Adult asthma biomarkers.
Kim MA; Shin YS; Pham le D; Park HS
Curr Opin Allergy Clin Immunol; 2014 Feb; 14(1):49-54. PubMed ID: 24300416
[TBL] [Abstract][Full Text] [Related]
36. The use of biological agents for the treatment of fungal asthma and allergic bronchopulmonary aspergillosis.
Moss RB
Ann N Y Acad Sci; 2012 Dec; 1272():49-57. PubMed ID: 23231714
[TBL] [Abstract][Full Text] [Related]
37. Anti-IgE therapy with omalizumab for severe asthma: current concepts and potential developments.
Pelaia G; Vatrella A; Busceti MT; Gallelli L; Terracciano R; Maselli R
Curr Drug Targets; 2015; 16(2):171-8. PubMed ID: 25523898
[TBL] [Abstract][Full Text] [Related]
38. Utility of serum periostin in combination with exhaled nitric oxide in the management of asthma.
Nagasaki T; Matsumoto H; Izuhara K;
Allergol Int; 2017 Jul; 66(3):404-410. PubMed ID: 28256388
[TBL] [Abstract][Full Text] [Related]
39. The effect of omalizumab on eosinophilic inflammation of the respiratory tract in patients with allergic asthma.
Kupryś-Lipińska I; Molińska K; Kuna P
Pneumonol Alergol Pol; 2016; 84(4):232-43. PubMed ID: 27435350
[TBL] [Abstract][Full Text] [Related]
40. Advances in the understanding of allergic asthma.
Frieri M
Allergy Asthma Proc; 2007; 28(6):614-9. PubMed ID: 18201423
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
